PMI Buys Israeli Marijuana Company for $650 Million

BusinessPMI by Jacky Yin
Jul.19.2023
PMI Buys Israeli Marijuana Company for $650 Million
Philip Morris International (PMI) is in the process of acquiring an Israeli medical marijuana company Syqe Medical for up to $650 million. Syqe's main product is said to be a medical marijuana-measured dose inhaler for pain relief.

On July 18, Israeli media outlet Calcalistech reported that Philip Morris International (PMI) is in the process of acquiring Israeli medical marijuana company Syqe Medical for up to $650 million. Syqe's main product is a medical marijuana-measured dose inhaler for pain relief.

 

菲莫国际加码医用大麻市场? 或以6.5亿美元收购以色列大麻公司
Syqe product | calcalistech

 

Acquisition of all shares for USD $650 million

According to the report, PMI will first invest $120 million to support the Syqe inhaler's approval by the U.S. Food and Drug Administration (FDA). If approval is granted through clinical trials, PMI will go on to purchase all remaining shares of the Israeli company for $650 million.

 

The deal will be carried out through PMI's subsidiary Vectura, which specializes in the inhaler space. PMI had acquired Vectura for £1 billion in 2021 as part of its strategy to transition to smoke-free world.

 

It is public information that in 2016, PMI made a $20 million investment in Syqe.

 

A number of independent patented technologies

If the acquisition goes through, it will be one of the biggest deals in the Israeli med-tech sector in recent years; and if it reaches a valuation of $650 million, Syqe will become one of the top 10 cannabis companies in the world.

 

Founded in 2011 by Perry Davidson, who still serves as CEO, Syqe holds around 120 patents, and its main innovations are the use of the raw inflorescence of the cannabis plant rather than processed products, and the ability to accurately measure the dosage given to patients.

 

It's worth noting that total investment in the company to date is $80 million, with Davidson holding more than 10 percent of the shares.

 

Currently, more than 80% of medical marijuana consumers use smoking products such as cigarettes and e-cigarettes, leading to potential overdoses, and Syqe's inhaler provides relief without the need for an overdose, avoiding the "psychoactive effect".

 

FDA approval is a key milestone

In the past, these inhalers were marketed and distributed through the Israeli pharmaceutical company Teva. Recently, however, Syqe has chosen to market independently and has entered into partnership agreements with the Ministry of Defense and Meuhedet HMO.

 

Syqe's primary target market is outside of Israel, and its FDA approval is a key milestone. According to the report, PMI will play an important role in getting Syqe through FDA approval. If successful, Syqe will be the first company in the world to receive FDA approval for the use of raw cannabis inflorescences as medicine.

 

PMI is one of the world's largest cigarette manufacturers with a market capitalization of $154 billion. In recent years, PMI has launched a new tobacco transformation strategy, and today more than one-third of its revenue comes from smokeless products, including heated tobacco products like IQOS.

 

According to PMI, the medical marijuana market is worth $24 billion, growing at a 15% annual rate through 2030. The wellness market, which includes cannabis-based tranquilizers and sleep aids, is estimated to be worth an additional $4 billion, with an 8% growth rate.

 

Syqe's inhaler is currently available in Israel and Australia, which are relatively small markets. The Israeli market is estimated at only NIS 100 million (approximately USD $27.5 million) per year, serving approximately 50,000 medical marijuana patients.

 

Reference:

【1】Philip Morris acquiring Cannabis inhaler developer Syqe Medical for up to $650 million

*The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the original author and refrain from forwarding directly from here.

UK Medicines Agency Announces in Late April: SKE, IVG, VOZOL Launch New Pod-Style Devices and Flavours
UK Medicines Agency Announces in Late April: SKE, IVG, VOZOL Launch New Pod-Style Devices and Flavours
2FIRSTS found that UK’s MHRA lists new SKUs from SKE, ELFBAR, IVG, VOZOL in late April. Products include pods and devices, mostly in fruit and smoothie flavors, with nicotine levels at 10mg/mL and 20mg/mL.
May.08 by 2FIRSTS.ai
ZYN Refreshes Packaging and Expands Line-Up in UK with Two New Flavours and Lower-Strength Options
ZYN Refreshes Packaging and Expands Line-Up in UK with Two New Flavours and Lower-Strength Options
Philip Morris International (PMI) has refreshed its ZYN nicotine pouch brand in the UK with a new packaging design and a range of flavour upgrades. The revamp includes the launch of an ultra-low strength 1.5mg option, as well as two new flavours: Spearmint and Apple Mint.
Jun.09 by 2FIRSTS.ai
U.S. Kentucky Attorney General Pledges Crackdown on Illegal Chinese E-Cigarettes Marketed to Minors
U.S. Kentucky Attorney General Pledges Crackdown on Illegal Chinese E-Cigarettes Marketed to Minors
Kentucky to crack down on Chinese e-cigarette targeting minors, with State Attorney General Russell Coleman leading the charge.
May.29 by 2FIRSTS.ai
Indonesia's Jakarta to Include E-Cigarettes in Smoke-Free Zone Rules in 2025
Indonesia's Jakarta to Include E-Cigarettes in Smoke-Free Zone Rules in 2025
Indonesia's Jakarta is advancing a draft law to include e-cigarettes in public smoking bans under its smoke-free zone regulations, targeting passage in 2025. The move aims to fill the regulatory gap for e-cigarettes and will be backed by fines and potential criminal liability to ensure compliance.
May.08 by 2FIRSTS.ai
KT&G Shifts HTP Production to Malaysia, 'lil Hybrid 3.0' Supply Normalizes
KT&G Shifts HTP Production to Malaysia, 'lil Hybrid 3.0' Supply Normalizes
South Korea's KT&G has moved its production of the "lil Hybrid 3.0" heated tobacco device from Vietnam to Malaysia, responding to Vietnam's impending ban on e-cigarettes and heated tobacco products. The relocation has resolved prior supply disruptions, with normal distribution resuming earlier this month. KT&G's "lil" series currently holds approximately 45.8% of South Korea's heated tobacco market, maintaining a lead over PMI.
May.09 by 2FIRSTS.ai
Celebrating a Decade: Vapouround Global Awards Held in Dubai, 2Firsts Invited for On-Site Coverage
Celebrating a Decade: Vapouround Global Awards Held in Dubai, 2Firsts Invited for On-Site Coverage
The Vapouround 10th Anniversary Global Awards Ceremony was grandly held in Dubai, bringing together brand representatives, industry experts, and opinion leaders from around the world. Multiple major awards were announced on-site to celebrate a decade of industry achievements. 2Firsts was invited to attend and provide on-site coverage.
Jun.19 by 2FIRSTS.ai